Impact of preconditioning stem cells with all-trans retinoic acid signaling pathway on cisplatin-induced nephrotoxicity by down-regulation of TGF\(\beta\)1, IL-6, and caspase-3 and up-regulation of HIF1\(\alpha\) and VEGF

Mohsen Khedra\(^a\), Nashwa Barakat\(^b\), Ibrahim Mohey El-Deen\(^a\), Faten Zahran\(^c\)

\(^a\) Department of Chemistry, Faculty of Science, Port Said University, Port Said, Egypt
\(^b\) Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
\(^c\) Department of Chemistry, Faculty of Science, Zagazig University, Zagazig, Egypt

ABSTRACT

The survival reduction after transplantation limited the clinical uses of stem cells so the current study explored preconditioning adipose-derived stem cells (ADMSCs) and all-trans retinoic acid (ATRA) effects on cisplatin that caused acute kidney injury (AKI). One hundred and fifty Sprague–Dawley male rats were distributed into five groups: control group; Cisplatin (CIS) group; CIS and ATRA group; CIS and ADMSC group, and CIS, ATRA, and ADMSCs group. Ten rats were euthanized after 3rd, 7th, and 11th days from CIS injection. Renal function, molecular studies, and histopathological analysis were studied. The preconditioning of ADMSCs with ATRA increased the viability of the cells which was reflected in the amelioration of kidney functions after CIS injection by the significant reduction of serum creatinine, microalbuminuria, as well as NO, and the significant rise of creatinine clearance, as well as SOD compared to the group of cisplatin. ATRA also supported ADMSCs by a significant down-regulation of caspase-3, il-6 and TGF\(\beta\)1, and a significant up-regulation of HIF1, VEGF and CD31 compared to group of cisplatin which reversed the cisplatin effect. ATRA increased renoprotective properties of ADMSCs against cisplatin-induced AKI by reducing the apoptosis, inflammation, and stimulating angiogenesis.

1. Introduction

Cisplatin is a highly effective medicine for many human malignancies, and, despite its effectiveness, high dose from cisplatin limited by accumulative and acute kidney toxicity (Shen et al., 2012). Acute kidney injury (AKI) is a serious and relatively side effect of CIS treatment, which can be seen in nearly 30% of patients after a single dose. Research indicated that CIS can induce nephrotoxicity by injury pathway, that contains the cisplatin conversion to toxic metabolites, damage of mitochondrial, and nuclear DNA, as well as ionic homeostasis disruption, the reactive oxygen species (ROS) release (Wang et al., 2020), induction of inflammation (Volarevic et al., 2019), as well as activation of the apoptotic pathway (Dugbartey et al., 2016).

Depending on the previous mechanisms, various renoprotective approaches were established. These approaches are categorized according to their main target: pathway of cell death, CIS uptake by renal cell, metabolism of CIS, oxidative stress and inflammation, and Cell-cycle regulators, (Pabla & Dong, 2008).

Mesenchymal stem cells (MSCs) are hopeful tools of therapeutic applications for stem cells as they are found in different sources, like adipose tissue, bone marrow, as well as an umbilical cord (Wei et al., 2013). However, the transplanted stem cells death, the reduction of their migration and the tissue damage by ROS, inflammation, apoptotic cascade activation, and poor vascular supply, make a critical barrier to their advantage (Pourjafar et al., 2011).
2. Materials and methods

2.1. Preparation of complete primary culture media

Briefly, under laminar airflow, Dulbecco's modified Eagle's medium (DMEM) media was aliquoted in 50 ml Falcon tubes and preserved at 2–8 °C. Fetal bovine serum (FBS) was well-kept at 2–8 °C and was put in the water bath, then aliquoted in 15 ml Falcon tubes. Penicillin/streptomycin antibiotic was preserved at −20 °C and was put in the water bath until thawed and then aliquoted in 15 ml Falcon tubes at a volume of 5 ml/tube and was preserved at −20 °C. Finally, the tubes, which contained 50 ml medium, 5 ml FBS (10%), and 0.5 ml penicillin/streptomycin antibiotic were filtered using a filter system with 250 ml and warmed in the water bath at 37 °C before used for cultures.

2.2. Preparation of adipose-derived MSCs

ADMSCs were obtained from a male Sprague–Dawley (SD) rat. Briefly, the rat was subjected to anesthesia, the para gonadal fat was obtained and was put in phosphate-buffered saline (PBS), and small pieces of fat were cut and centrifuged 10 min at 2000 rpm. After that, collagenase I 0.075% (Sigma, USA) was used for putting the fat inside it at 37 °C for 1 h to complete digestion and was centrifuged for 10 min at 2000 rpm. The pellet was resuspended in PBS, while the formed supernatant was removed, and the pellet was centrifuged again 10 min at 2000 rpm.

The DMEM supplemented with 10% FBS (GIBCO, Thermo, USA) was used to resuspend the pellet, and it was transferred to a tissue culture flask and kept in a 5% CO2 incubator. Two times weekly, the medium was replaced till the cells reached 70% – 80% confluence, and treated with 1 mM EDTA (Invitrogen, Thermo, USA) and 0.25% trypsin 3 min. At the same culture conditions, the ADMSCs were replaced in a 1:3 split ratio. After the third passage, cells were used for experiment.

2.3. Flow cytometric analysis

Adipose stem cells were trypsinized to release stem cells and investigated by flow cytometry, where the cells were washed two times by PBS, and then aliquots of cells were prepared at (1×106/ml) concentration and then incubated at 25 °C in the dark for 30 min with following antibodies: Phycoerythrin (PE)-conjugated CD45 and PE-conjugated CD105. After that, labeled cells were washed by PBS then detected by flow cytometer (Beckman Coulter, USA).

2.4. Pretreatment of ADMSCs with retinoic acid and a cell viability assay

The colorimetric MTT assay was used for cell viability assessment, where ADMSCs were first pretreated with different concentrations of ATRA as follows: the cells were put at 5×103 cell/well, ATRA was used at various concentrations (0, 0.5, 1, 5, and 10 μmol/L) for the treatment of the ADMSCs. After that, cells with ATRA were incubated for 24 and 48 h; after incubation, 3-(4, 5-di methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma Aldrich, USA) was incubated with the cells at 37 °C for 4 h and 100 μl DMSO (Sigma–Aldrich) was added. At a wavelength 570 nm, an automatic microplate reader is used to detect the optical density of the solubilized formazan.

2.5. Animals

150 male Sprague Dawley (SD) rats, weighing approximately 180–230 g were well-kept at standard conditions and a temperature fixed at 20 °C. All the experiments were conducted in conformity with the Urology and Nephrology Center, Mansoura University, guidelines for the care and use of laboratory animals (ILAR 1996), and were approved by Mansoura University, Mansoura, Egypt ethics committee (Code # MDP.19.12.35.R1).

2.6. Experimental design

Normal group (n = 30): This group was injected with 1 ml 0.9% saline intraperitoneal (IP). (Cisplatin ‘CIS’ group) (n = 30): This group was injected IP by 6 mg/kg CIS as a single dose. CIS and ATRA group (n = 30): This group was injected IP by cisplatin at 6, and, after one day of injection, the rats were injected intravenously with 10 μM ATRA. CIS and ADMSCs group (n = 30): Rats were injected with 0.5 ml of culture media containing 1×106 ADMSCs in the tail vein. CIS, ATRA, and adipose-ADMSCs group (n = 30): This group was injected IP by CIS at 6 mg/kg, and, after one day from the injection, the rats were injected intravenously with 1×106 ADMSCs pre-conditioned for 48 h with 10 μM ATRA. Before the sacrifice of each group, urine samples were collected randomly for the estimation of microalbuminuria (MAU), and then, the urine was collected during one day. The volume of urine was determined, and the urinary creatinine was calculated. Then, 10 rats in each group were sacrificed at days 3, 7, and 11 after treatment, and the kidney tissue and blood samples were obtained.

2.7. Biochemical measurements

The blood samples were obtained from hearts of all rats in blood vacationer tubes without any anticoagulant. The tubes were centrifuged for 10 min at 4000 r.p.m at 25 °C, the serum creatinine was determined using the Architect c4000 system (Abbott Diagnostics, Wiesbaden, Germany). Microalbuminuria (MAU) was determined in the urine samples according to Cambiaso et al. (1988) (Cambiaso et al., 1988), by using the Albumin (Microalbuminuria) Kit (COD: 31924), supplied by (Biosystem S.A., 30 08,030 Barcelona (Spain). The creatinine clearance was measured from the following equation (Mahmoud et al., 2007).
\[
\text{CrCl (mL/min) = } \frac{\text{Urine creatinine (mg/dL) \times urine volume (mL/24 h)}}{\text{(Serum creatinine (mg/dL) \times 1440 (min))}}
\]

2.8. Assay of nitric oxide marker (NO) and antioxidant (SOD enzyme activity) in kidney tissues

Nitric oxide was determined in kidney tissue colorimetrically using (Biodiagnostic, Egypt). Nitrate was reduced to nitrite by adding Vanadium trichloride to the supernatant according to Miranda et al.’s method (Miranda et al., 2001), while superoxide dismutase activity in kidney tissues was estimated colorimetrically using (Biodiagnostic, Egypt).

2.9. Real-time PCR for TGF\(\beta1\), IL-6, VEGF, HIF1\(\alpha\), and Caspase-3 genes

The Trizol reagent (Invitrogen Corporation, New York) extracted the total RNA from kidney tissues. cDNA reverse transcription kit (Applied Biosystem, USA) used to synthesize cDNA from 1 \(\mu\)g RNA. RT-PCR investigation was done by SYBER Green PCR Master Mix (Biosystem, USA) and performed using an Applied Biosystem (Step One\(\text{TM}\), USA).

The PCR reaction was 1 cycle for 2 min at 50 °C for amplification, then 40 cycles, each cycle containing denaturation for 15 s at 95 °C, annealing for 1 min at 60 °C, and elongation for 1 min at 72 °C. Relative expression of VEGF, IL-6, Caspase-3, TGF\(\beta1\) and HIF1\(\alpha\) was calculated using the 2\(^{-}\Delta\Delta Ct\) method. Selective primer sequences of genes are listed in Table 1.

2.10. Histopathological examination

Kidney specimens were fixed in paraffin; specimens were cut into 4-\(\mu\)m thick slices by a microtome (Leica RM 2155, England) then stained with hematoxylin and eosin to examine under light microscopic at 400x magnification. The scoring system (Nasir et al., 2011) regarded active injury changes as those that comprise mitotic figures and solid sheets between the tubules.

2.11. Study of renal caspase-3 by immunohistochemical examination

The immunohistochemistry staining assay was done to assess the renal caspase-3, where the paraffin-embedded slices of kidney tissues (3 \(\mu\)m thickness) were first deparaffinized, then incubated for 30 min with goat serum 5% (Sigma–Aldrich), and then with hydrogen peroxide 3% (Fisher Scientific) for 15 min for the activation of endogenous enzymes.

After that, the slides were incubated with activated caspase-3 antibodies (RB-1197-P1; Fremont Blvd, Fremont, CA, USA) at 4 °C overnight, then incubation 30 min with biotinylated secondary antibody (Power - Stain 1.0 Poly HRP DAB Kit), and then, the slides were incubated with Vectastain Elite ABC reagent for 30 min, followed by diaminobenzidine (DAB) incubation for 2 min, and hematoxylin counterstaining for 1 min; the sections examined with an Olympus BX51 light microscope.

2.12. Immunofluorescence examination

The slices of kidney tissues were prepared using a cryostat and mounted on super frost slides, and then we performed the blocking step. The slides were incubated in 5% normal serum for 1 h, the blocking solution was aspirated followed by incubation with CD31 (BBA7) at 25 °C for 1 h, and then the slides were incubated with anti-rabbit IgG for 1 h at RT in the dark. The slides were developed with diaminobenzidine (DAB) (California, USA) staining. Kidney tissue sections were examined using fluorescent microscope licea for positive nuclei. The expression of CD31 was measured as follows: the number of CD31 positive nuclei was calculated in 10 fields at 200 X, and then we calculated the mean number of positive nuclei (Xue et al., 2018).

2.13. Statistical analysis

The results are expressed as the mean ± standard deviation, and statistical differences were determined using one-way analysis of variance (ANOVA) taking \(p < 0.05\) as the confidence interval. All statistical analyses were performed using SPSS version 20 (IBM Corp., USA).

3. Results

3.1. Isolation and characterization of ADMSCs

Using flow cytometric analysis, the cultured cells expressing a CD105 positive rate were 84.5%, and the negative rate of CD105 was 15.5%, while the positive rate of CD45 was only 8.7%, and the negative rate was 91.3%. These results are in accordance with the expression characteristics of surface antigens of ADMSCs (Fig. 1 a, b).

3.2. ATRA increased ADMSC viability

The third passage of ADMSCs (Fig. 2a) pretreated with ATRA showed fibroblast-like morphology and increased regeneration (Fig. 2b). As shown in Fig. 3, ATRA significantly improved the proliferation of ADMSC at 24 and 48 h. The cellular viability was...
significantly increased in all treated ADMSCs except for 0.5 μmol/L ATRA for 24 and 48 h compared to control (P < 0.05). The viability reached the maximum increase in concentration 10 μmol/L at 48 h compared to 10 μmol/L at 24 h (P < 0.05).

3.3. Biochemical parameters

The serum creatinine (Scr), microalbuminuria (MAU) in mg/dl, and creatinine clearance (CrCl) in ml/min of all the studied groups are shown in Table 2. The mean basal Scr, MAU, and CrCl were compared among the different groups. Scr and MAU were significantly increased in the CIS group compared with the control group (P ≤ 0.05) at 3, 7, and 11 days. CrCl showed a significant decrease in the CIS group compared with the control group. Groups treated with ADMCs alone or ADMCs pretreated with ATRA had a significant decrease in Scr and MAU levels and a significant rise in CrCl compared to the CIS group (P ≤ 0.05) at different endpoints.

3.4. Oxidative stress and antioxidants parameters

As shown in Table 3, CIS increased the renal NO compared to the control group. The administration of ADMSCs alone or pretreated with ATRA to CIS rats reduced the renal NO concentrations compared to the CIS group. SOD activity was significantly decreased in CIS group compared with the control group (P < 0.05). ADMSCs significantly increased renal SOD levels. ADMSCs pretreated with ATRA showed the most increase in SOD compared to the control group (P ≤ 0.05) at the three times intervals.

3.5. Effects of ADMSCs on renal TGFβ1, IL-6, VEGF, HIF1α, and Caspase-3 expression

The inflammatory marker TGFβ1 and IL-6, angiogenesis markers VEGF and HIF1α, and apoptotic marker Caspase-3 revealed a significant up-regulation in CIS group compared to the control group. The ADMSCs alone or pretreated with ATRA groups showed a significant down-regulation in TGFβ1, IL-6, and caspase-3 compared to the CIS group, and they showed a significant up-regulation in HIF1α and VEGF compared to the CIS group at all-time intervals (Fig. 4).

3.6. Histopathological examination

Injury of the kidney tubules was quantified using a scoring system, the effects of retinoic acid, ADMSCs, and a combination of both on the tubulointerstitial damage score at different time intervals (Fig. 5A). The normal group presented normal kidney architecture (Fig. 5B). In the cisplatin-induced injury group, apoptosis, dilated irregular tubules, and interstitial inflammatory infiltrate were detected at the different time intervals (Fig. 5C, D).

Table 2

| Groups | 3d | 7d | 11d |
|--------|----|----|-----|
|        | Basal | Test | Basal | Test | Basal | Test |
| SCR (mg/dl) | | | | | | |
| Control | 0.51 ± 0.03 | 0.55 ± 0.04 | 0.45 ± 0.02 | 0.57 ± 0.04 | 0.46 ± 0.03 | 0.56 ± 0.05 |
| CIS | 0.42 ± 0.11 | 5.27 ± 0.76* | 0.48 ± 0.11 | 3.52 ± 0.45* | 0.45 ± 0.12 | 1.79 ± 0.62* |
| ATRA | 0.43 ± 0.12 | 3.11 ± 0.60 ab | 0.43 ± 0.01 | 2.35 ± 0.64ab | 0.43 ± 0.10 | 1.44 ± 0.44a |
| ADMSCs | 0.44 ± 0.14 | 2.71 ± 0.55abc | 0.42 ± 0.12 | 1.74 ± 0.34abc | 0.42 ± 0.11 | 1.15 ± 0.21ab |
| ATRA + ADMSCs | 0.43 ± 0.10 | 2.23 ± 0.41abc | 0.43 ± 0.12 | 1.52 ± 0.53abc | 0.41 ± 0.09 | 0.84 ± 0.05ab |
| MAU (mg/dl) | | | | | | |
| Control | 1.06 ± 0.16 | 1.02 ± 0.11 | 1.09 ± 0.22 | 1.01 ± 0.22 | 1.03 ± 0.2 | 0.96 ± 0.15 |
| CIS | 1.09 ± 0.28 | 9.75 ± 1.00 * | 1.02 ± 0.38 | 5.41 ± 1.09 * | 0.92 ± 0.2 | 2.83 ± 0.75 * |
| ATRA | 0.92 ± 0.2 | 5.78 ± 0.77 ab | 0.92 ± 0.18 | 4.13 ± 0.55 ab | 0.92 ± 0.18 | 2.15 ± 0.41 ad |
| ADMSCs | 0.95 ± 0.1 | 4.38 ± 0.73 abc | 0.93 ± 0.17 | 3.21 ± 0.57 ab | 0.93 ± 0.17 | 1.78 ± 0.62 ab |
| ATRA + ADMSCs | 0.93 ± 0.16 | 3.19 ± 0.43abcd | 0.94 ± 0.12 | 2.53 ± 0.58abcd | 0.89 ± 0.17 | 1.33 ± 0.44ab |
| CrCl (ml/min) | | | | | | |
| Control | 1.64 ± 0.51 | 1.69 ± 0.43 | 1.59 ± 0.31 | 1.65 ± 0.52 | 1.67 ± 0.25 | 1.72 ± 0.61 |
| CIS | 1.48 ± 0.58 | 0.21 ± 0.04a | 1.32 ± 0.28 | 0.48 ± 0.08a | 1.56 ± 0.75 | 0.63 ± 0.09ab |
| ATRA | 1.64 ± 0.49 | 0.53 ± 0.04ab | 1.63 ± 0.51 | 0.71 ± 0.11ab | 1.89 ± 0.66 | 0.91 ± 0.15ab |
| ADMSCs | 1.75 ± 0.51 | 0.67 ± 0.14ab | 1.97 ± 0.48 | 0.82 ± 0.16abc | 2.04 ± 0.58 | 1.04 ± 0.11abc |
| ATRA + ADMSCs | 1.81 ± 0.71 | 0.98 ± 0.09abcd | 1.99 ± 0.92 | 1.24 ± 0.29abcd | 2.12 ± 0.77 | 1.58 ± 0.37 abc |

Data are expressed as the means ± SD of thirty rats per group. Significant difference from the *control group, *cisplatin group, *retinoic acid group, and *stem cell group using one-way analysis of variance (ANOVA) followed by the post hoc test for multiple comparison (Scheffé test) at (P ≤ 0.05).
However, when the rats were treated with ATRA (Fig. 5E) and/or ADMSCs (Fig. 5F), less inflammation with prominent nuclei compared to the CIS group was observed. At the same time, the ADMSCs pretreated with the ATRA group showed the lowest inflammation and little apoptosis with prominent nuclei and mitotic figures compared to the CIS group (Fig. 5G).

### 3.7. Immunohistochemical observation

The caspase-3 immunopositivity was presented in the renal tubules in different treated groups at different times (Fig. 6A). The immunohistochemistry staining revealed a negative caspase-3 expression in the control group (Fig. 6B), while the CIS group exposed a significant increase in caspase-3 compared to the control group (Fig. 6C). The ATRA and ADMSC groups indicated a significant reduction in caspase-3 (Fig. 6D, E), with maximum significant attenuation in ADMSCs pretreated with ATRA group compared with the CIS group (Fig. 6F).

### Table 3
Effects of ADMSCs pretreated with ATRA on the kidney nitric oxide (NO) (μmol/l) level and super oxide dismutase (SOD) concentration.

| Groups                  | 3 d     | 7 d     | 11 d    |
|-------------------------|---------|---------|---------|
| NO (μmol/l)             |         |         |         |
| Control                 | 10.21 ± 0.1 | 10.27 ± 0.15 | 10.2 ± 0.2 |
| CIS                     | 55.38 ± 1.1* | 51.98 ± 1.14* | 43.94 ± 2.35* |
| ATRA                    | 40.7 ± 1.007* | 33.7 ± 1.45* | 31.7 ± 1.18* |
| ADMSCs                  | 28.5 ± 1.63* | 24.5 ± 1.6* | 20.1 ± 1.1* |
| ATRA + ADMSCs           | 21.26 ± 0.6* | 17.7 ± 1.26* | 14.11 ± 0.47* |
| SOD (U/mg tissue)       |         |         |         |
| Control                 | 5.46 ± 0.5 | 5.48 ± 0.24 | 5.53 ± 0.2 |
| CIS                     | 1.17 ± 0.18* | 1.2 ± 0.11* | 1.4 ± 0.08* |
| ATRA                    | 1.98 ± 0.11* | 2.27 ± 0.17* | 2.6 ± 0.15* |
| ADMSCs                  | 2.5 ± 0.13* | 3.00 ± 0.13* | 4.6 ± 0.13* |
| ATRA + ADMSCs           | 3.4 ± 0.09* | 3.9 ± 0.1* | 4.71 ± 0.15* |

Data are expressed as the means ± SD of thirty rats per group. Significant difference from the *control group, c*cisplatin group, *r*etinoic acid group, and *s*tem cell group using one-way analysis of variance (ANOVA) followed by the post hoc test for multiple comparison (Scheffe test) at (P ≤ 0.05).

Fig. 4. Effect of ADMSCs pretreated with ATRA on a) TGFβ1, b) IL-6, c) VEGF, d) HIF1α, and e) Caspase-3 gene expression.
3.8. Immunofluorescent examination of CD31

The immunofluorescent score is shown in Fig. 7A, and the CD31 staining of the cytoplasmic membranes for endothelial cells of the peritubular capillaries showed no significant change between the cisplatin and control groups (Fig. 7B, C), while the treated groups with either ATRA (Fig. 7D) or ADMSCs (Fig. 7E) caused a significant rise in CD31 compared with CIS group, with the maximum significant increase in ADMSCs pretreated with ATRA group (Fig. 7F).

4. Discussion

Recently, therapeutic applications of stem cells have arisen as an attractive approach for supporting therapy for numerous diseases. However, implantation of stem cells has talented therapeutic application for the treatment of renal syndromes; it has not reached achievements of drug delivery. Thus, approaches of pretreatment are needed to rise stem cells efficacy before transplantation (Yu et al., 2013). The aim of this study was to evaluate the effect of ATRA on the proliferation and survival of ADMSCs and to study the effects on the improvement of their activity in acute kidney injury induced by cisplatin.

ATRA is an important signaling molecule, as it regulates many transcription factors. Many studies stated that ATRA plays a role to protect kidney against renal syndromes (Li et al., 2013). In many experimental types of the kidney syndrome, ATRA was exposed to protect against renal damage. Research showed that rats with experimental mesangio-proliferative glomerulonephritis treated with ATRA demonstrated inhibition of albuminuria (Lazzeri et al., 2014).

In our study, CIS caused damage to the kidneys, which was proven by the levels of serum creatinine and microalbuminuria, which markedly increased following CIS injection, and creatinine clearance markedly reduced compared to the control group. This is due to direct toxicity made by ROS after cisplatin injection as previously reported (Elhusseini et al., 2016).

For the rats treated with ATRA and treated with ADMSCs, the level of serum creatinine and microalbuminuria significantly decreased compared with CIS group. Similarly, creatinine clearance significantly increased in contrast to that in the CIS group. The ADMSCs treated with ATRA group showed stronger decreases in the serum creatinine and microalbuminuria and increases in the creatinine clearance almost to the normal level and pretreatment of ADMSCs with ATRA was capable of ameliorating renal dysfunction by increasing the paracrine effect of the ADMSCs (Pourjafar et al., 2017).

Cisplatin produces reactive oxygen species (ROS) by causing mitochondrial dysfunction. ROS in renal cells reduce the antioxidant enzyme activity and intracellular concentrations of antioxidants (Ozkok & Edelstein, 2014). CIS increased NO concentration while decreased SOD activity compared to control, which
was discussed in the previous studies (Gad et al., 2017; Kara et al., 2019). ADMSCs administration reduced AKI by suppressing oxidative stress (Kinnaird et al., 2004). ATRA was also reported to have a free radical scavenger effect (Shi et al., 2017), and that explained our results, which showed that the pretreatment of ADMSCs with ATRA improved SOD activity and decreased NO concentration compared to ADMSCs alone.

Recently, studies stated that ATRA has an anti-inflammatory effect, and this effect was exposed in a mouse model of lupus nephritis and in anti-glomerular basement membrane glomerulonephritis in rats (Lazzeri et al., 2014). Transforming growth factor-β1 (TGF-β1) induces the release of fibroblasts and inflammatory cells into the injury part (Elsherbiny et al., 2016).

Our results showed that CIS caused elevation in the TGFβ1 and IL-6 expression, and this was in agreement with previous studies (Elseweidy et al., 2018; Aboul-Naga et al., 2020). The ADMSCs injection pretreated with ATRA to rats treated with CIS reduced the expression of TFG-β1, IL-6, and this was compatible with Li et al. (2013).

HIF-1 has a particular role in regulating oxygen homeostasis, mitochondrial respiration, and protecting the kidneys against CIS-induced tubular cell apoptosis, and any interference with it leads to increased ROS levels and apoptosis. The protein expression of HIF-1α in their CIS group was significantly increased when compared to the control group (Liu et al., 2015).

CIS with ADMSCs group presented significantly increase in HIF-1α expression. Hussein et al. (2016) established that ADMSCs protect the kidneys against ischemic-reperfusion damage by endoplasmic reticulum stresses and oxidative reduction of the HIF-1α activation. The expression became more marked in the CIS treated with both ATRA and ADMSCs group, which was in line with Fernandez Martinez et al. (2013), who established that ATRA induced HIF-1α expression in human renal proximal tubular (HK2) cells and Pourjafar et al. (2016), who presented that ATRA improved HIF-1 mRNA level compared with untreated ADMSCs.

Kidney damage, including the infiltration of leukocytes, tubules dilation, and degenerative changes in the epithelium of the tubule lumens, was shown after CIS therapy by microscopic examination. These results were compatible with Elhusseini et al. (2016) findings (Elhusseini et al., 2016). Treatment with ADMSCs prior to CIS reversed oxidative damage, inflammation, and apoptosis in kidneys and, consequently, regenerated kidney cells, improved the structure, and prevented acute kidney injury and histopathological damage starting from day 3, which was compatible with Sakr et al. (2017). ATRA treatment was found to suppress interstitial mononuclear cell infiltration, and ATRA treatment for puromycin aminonucleoside nephrosis decreased proteinuria and reduced leukocyte infiltration (Lazzeri et al., 2014).

Previous studies indicated that CIS led, principally, to the apoptosis of renal tubular cells (Iwayama and Ueda, 2013). According to the gene and protein expression of caspase-3, we realized the ability of pretreated ADMSCs with ATRA to reduce the activity of caspase-3 and, thus, to reduce apoptosis. This is in agreement with Pourjafar et al. (2017), who documented that caspase-3 significantly inhibited in ATRA-treated ADMSCs so ATRA has ability to rise the viability of stem cells and stimulate the ADMSCs proliferation by reducing caspase-3 activity (Pourjafar et al., 2017).
The role of angiogenesis potentiality as a cytoprotective effect of stem cell therapy was discussed in several studies. Vascular endothelial growth factor (VEGF) involved in vasculogenesis and angiogenesis, while CD31 is an endothelial cell marker that is upregulated during renal injury (Awadalla et al., 2021). This study found that the VEGF gene and CD31 protein increased in the CIS group. Also has shown that ATRA has high effects on vasculogenesis and angiogenesis.

ADMSCs pretreated with ATRA caused the CD31 overexpression in the endothelial cells of blood vessels of kidney tissues compared to ADMSC alone, and this may be due to the vascular inflammation and leakage of leukocytes from the blood vessels into the tissues, which was in accordance with El-Beltagy and Elghaweet (2016), who documented that endothelial cells have an important role in tissue repair, inflammation, and angiogenesis.

One of our study limitations is in understanding the mechanism of ATRA in increasing ADMSCs’ efficacy in leading to the improvement of the kidney structure after CIS therapy. ATRA may act as an inducer for several chemokine receptors and angiogenic factors. Further studies are necessary to confirm the role of preconditioning ADMSCs with ATRA in the nephrotoxicity area.

5. Conclusion

The current study revealed the effect of ATRA on the viability and proliferation of ADMSCs. Moreover, the renoprotective potentiality of ADMSCs was enhanced by the pretreatment with ATRA. This improvement was detected in restoring the antioxidant and free radical balance, decreasing the inflammation and the apoptosis induced by cisplatin. Therefore, ADMSCs- ATRA pretreatment before transplantation could be essential for the development of clinically applicable interventions.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

I am especially grateful to all the staff members of the Research Department, Urology and Nephrology Center, Mansoura University, and to everyone who gave me a hand throughout this study for help and support.

References

Aboul-Naga, A.M., Hamam, E.T., Awadalla, A., Shokeir, A.A., 2020. The protective role of l-carnitine on spermatogenesis after cisplatin treatment during prepubertal period in rats: A pathophysiological study. Life Sci. 258, 118242. https://doi.org/10.1016/j.lfs.2020.118242.

Awadalla, A., Hussein, A.M., Ali, M., Barakat, N., Hamam, E.T., Magar, R.W., Shokeir, A.A., 2021. Possible mechanisms for the renoprotective action of adipose-derived mesenchymal stem cells with CD44-targeted hyaluronic acid against renal ischemia. Life Sci. 272, 119221. https://doi.org/10.1016/j.lfs.2021.119221.

Cambraio, C., Collet-Cassart, D., Lievens, M., 1988. Immunoassay of low concentrations of albumin in urine by latex particle counting. Clin. Chem. 34 (2), 416–418.

Dugbaraty, G.J., Peppone, l.J., de Graaf, I.A.M., 2016. An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures. Toxicology 371, 58–66.

El-Beltagy, A.-F., Elghaweet, H.A., 2016. Adverse effects of monosodium glutamate on the reproductive organs of adult female albino rats and the possible ameliorated role of carob (Ceratonia Siliqua). J. Biosci. Appl. Res. 2 (3), 170–184.
Elhusseini, F.M., Saad, M.-A.-A., Anber, N., Elghannam, D., Sobh, M.-A., Alsayed, A., El-Dusoky, S., Sheashaa, H., Abdel-Gaffar, H., Sobh, M., 2016. Long term study of protective mechanisms of human adipose derived mesenchymal stem cells on cisplatin induced kidney injury in sprague-dawley rats. J. Stem Cells & Regenerative Med. 12 (1), 36.

Elsewedy, M.M., Aiskar, M.E., Elsewedy, S.E., Shawky, M., 2018. Nephrotoxicity induced by cisplatin intake in experimental rats and therapeutic approach of using mesenchymal stem cells and spinorionalcatoic. Appl. Biochem. Biotechnol. 184 (4), 1390–1403.

Elisherhiny, N.M., Eladl, M.A.-G., Al-Gayyar, M.M., 2016. Renal protective effects of arginine acid in a cisplatin-induced nephrotoxicity model. Cytokine 77, 26–34. https://doi.org/10.1016/j.cytj.2015.10.010.

Fernández-Martínez, A.B., Gazzà, F.J.L., 2013. Epidermal growth factor receptor transactivation by intracellular prostaglandin E2-activated prostaglandin E2 receptors. Role in retinoic acid receptor-βi up-regulation. Biochim. Biophys. Acta (BBA)-Mol. Cell Res. 1833 (9), 2029–2038.

Gad, A.M., El-Raouf, O.M.A., El-Sayeh, B.M., Fawzy, H.M., Abdallah, D.M., 2017. Renoprotective effects of montelukast in an experimental model of cisplatin nephrotoxicity in rats. J. Biochem. Mol. Toxicol. 31 (12), e21979. https://doi.org/10.1002/jbt.2017.31.issue-12.e21979.

Hussein, A.M., Barakat, N., Awadalla, A., Gabr, M.M., Khater, S., Harraz, A.M., Shokeir, A.A., 2016. Modulation of renal ischemia/reperfusion injury in rats by a combination of ischemic preconditioning and adipose-derived mesenchymal stem cells (ADMSCs). Can. J. Physiol. Pharmacol. 94 (9), 936–946.

Iwayama, H., Ueda, N., 2013. Role of mitochondrial Bax, caspases, and MAPKs for ceramide-induced apoptosis in renal proximal tubular cells. Mol. Cell. Biochem. 379 (1-2), 37–42.

Kara, A.V., Aldemir, M.N., Ozciek, F., Mammadov, R., 2019. Protective effect of taxifolin on cisplatin-induced nephrotoxicity in rats. Anal. Quantitative Cytopathology and Histopathology 41 (2), 47–54.

Kimnaird, T., Stabile, E., Burnett, M.S., Sou, M., Lee, C.W., Barr, S., Fuchs, S., Epstein, S.E., 2004. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 109 (12), 1543–1549.

Lazzari, E., Peited, A.J., Lagagnani, P., 2014. Retinoids and glomerular regeneration. Paper presented at the Seminars in nephrology.

Li, Y., Cheng, C.N., Verdun, V.A., Wingert, R.A., 2014. Zebrafish nephrogenesis is regulated by interactions between retinoic acid, mecoma, and Notch signaling. Dev. Biol. 386 (1), 111–122.

Li, Z.-Y., Zhou, T.-B., Qin, Y.-H., Su, L.-N., Xu, H.-L., Lei, F.-Y., 2013. All-trans retinoic acid attenuates the renal interstitial fibrosis lesion in rats but not by transforming growth factor-β1/Smad3 signaling pathway. Ren. Fail. 35 (2), 262–267.

Liu, X., Huang, Z., Zou, X., Yang, Y., Qu, Y., Wen, Y., 2015. Possible mechanism of PNS protection against cisplatin-induced nephrotoxicity in rat models. Toxicol. Mech. Methods 25 (5), 347–354.

Mahmoud, L.M., Hussein, A.-E.-A.-M., Sarhan, M.E., Awad, A.A., El Desoky, I., 2007. Role of combined L-arginine and prostaglandin E1 in renal ischemia-reperfusion injury. Nephron Physiology 105 (4), 57–p65.

Miranda, K.M., Espey, M.G., Wink, D.A., 2001. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 5 (1), 62–71.

Nasir, A., Lopez, A., Boulware, D., Malafa, M., Coppola, D., 2011. Correlation between COX-2 and APC expression in left versus right-sided human colon cancer. Anticancer Res. 31 (6), 2191–2195.

Ozkok, A., Edelstein, C.L., 2014. Pathophysiology of cisplatin-induced acute kidney injury. BioMed Res. Int., 2014.

Pabla, N., Dong, Z., 2008. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 73 (9), 994–1007. https://doi.org/10.1038/sj.ki.5002786.

Pourjafar, M., Saidjam, M., Mansouri, K., Ghasemiazar, H., Karimi dermani, F., Najafi, R., 2017. All-trans retinoic acid preconditioning enhances proliferation, angiogenesis and migration of mesenchymal stem cell in vitro and enhances wound repair in vivo. Cell Profl. 50 (1), e12315. https://doi.org/10.1111/cpr.2017.50.issue-12.e12315.

Sakr, A.E., Abd Elhiai, W., Abo Zed, A., Ali, H., 2017. Transplanted adipose derived mesenchymal stem cells attenuate the acute renal injury induced by cisplatin in rats. Egypt. J. Histol. 40 (2), 169–183.

Shen, D.-W., Pouliot, L.M., Hall, M.D., Gottesman, M.M., Sibley, D.R., 2012. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. PharmacoL Rev. 64 (3), 706–721.

Shi, H., Yuan, L., Yang, H., Zang, A., 2017. The mechanism of all-trans retinoic acid in the regulation of apelin expression in vascular endothelial cells. Bioch. Rep. 37 (6), Volarevic, V., Djokovic, B., Jankovic, M.G., Harrell, C.R., Fellabaum, C., Djonov, V., Arsenjevic, N., 2019. Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J. Biomed. Sci. 26, 25.

Wang, Z., Sun, W., Sun, X., Wang, Y., Zhou, M., 2020. Kaempferol ameliorates Cisplatin induced nephrotoxicity by modulating oxidative stress, inflammation and apoptosis via ERK and NF-κB pathways. AMB Express 10, 58.

Wei, X., Yang, X., Han, Z.-F., Qu, F.-F., Shao, Li, Shi, Y.-F., 2013. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol. Sin. 34 (6), 747–754.

Wingert, R.A., Davidson, A.J., 2011. Zebrafish nephrogenesis involves dynamic spatiotemporal expression changes in renal progenitors and essential signals from retinoic acid and irx3b. Dev. Dyn. 240 (8), 2011–2027.

Xue, A., Niu, G., Chen, Y., Li, K., Xiao, Z., Luan, Y., Sun, C., Xie, X., Zhang, D., Du, X., Kong, F., Guo, Y., Zhang, H., Cheng, C., Xin, Q., Guan, Y., Zhao, S., 2018. Recellularization of well-preserved decellularized kidney scaffold using adipose tissue-derived stem cells. J. Biomed. Mater. Res. Part A 106 (3), 805–814.

Yu, S.P., Wei, Z., Wei, Z., Wei, L., 2013. Preconditioning strategy in stem cell transplantation therapy. Translational Stroke Res. 4 (1), 76–88.

Yucel, C., Erdogan Yucel, E., Arslan, P.D., Ekmenli, S., Kisa, E., Ulker, V., Ucar, M., Ilbey, Y.O., Celik, O., Isibilen Basok, B., Kozacioglu, Z., 2019. All-trans retinoic acid prevents cisplatin-induced nephrotoxicity in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 392 (2), 159–164. https://doi.org/10.1007/s00021-018-1663-0.